DEALS: Abbott buys Kos in $3.7B deal

DEALS

WHO

WITH

WHAT

SCOOP

Abbott Laboratories

Kos Pharmaceuticals

$3.7B buyout

Kos makes Niaspan and Advicor, which boost "good" cholesterol, and is in late-stage development of Simcor.

Merck

Sirna Therapeutics

$1.1B buyout

Sirna's lead drug candidate, Sirna-027, is being developed as a treatment for wet, age-related macular degeneration.

Allergan

Groupe Corneal Laboratoires

$216M buyout

Allergan, which makes Botox, plans to separate the French companies' aesthetic and ophthalmic business with an eye to selling the ophthalmic division.

Wyeth

Ablynx

$212M licensing deals

Ablynx has agreed to license its Nanobodies technology to Wyeth.

Lonza

Genentech

$150M purchase

Switzerland's Lonza has struck a deal to buy a manufacturing plant in Spain from Genentech.

Inspire Pharmaceuticals

FAES Farma

$89M licensing deal

Inspire Pharmaceuticals gains U.S. and Canadian licensing rights to bilastine.

Wyeth

Inovio Biomedical

$64.5M deal

Wyeth will use Inovio Biomedical's DNA delivery technology for certain DNA vaccines in development.

Roche

InterMune

$60M deal

Roche has signed a deal to develop InterMune's experimental therapy for hepatitis C.

Biomira

ProlX Pharmaceuticals

$23.9 buyout

The acquisition will give Biomira control of Stimuvax, a synthetic MUC1 peptide vaccine now in Phase III, and PX-12, a thioredoxin inhibitor which is headed into Phase II.

Cephalon

Ambit

$18 deal

Cephalon is gaining access to Ambit's proprietary KinomeScan technology.

Merck

J. David Gladstone Institutes

$3.25M collaboration and licensing pact

The groups have signed a collaboration and licensing pact for the research and development of drugs to treat neurodegenerative diseases.